News from samsung biologics A wide array of domestic and global news stories; news topics include politics/government, business, technology, religion, sports/entertainment, science/nature, and health/lifestyle.

Latest

May 21, 2020, 19:11 ET GSK partners with Samsung Biologics to secure additional manufacturing capacity for innovative biopharmaceutical portfolio

GlaxoSmithKline plc (LSE/NYSE: GSK) and Samsung Biologics (207940.KS) have entered into a partnership to provide GSK with additional capacity to...

May 19, 2020, 19:11 ET Samsung Biologics Expands Business Continuity Excellence with Additional ISO22301 Certification

Samsung Biologics (207940.KS) announced it has attained ISO22301 certification for additional business operations, demonstrating its unsurpassed...

Apr 22, 2020, 20:00 ET Samsung Biologics and ImmuneOncia Therapeutics Inc. Development and Manufacturing Agreement Accomplishes IND Clearance of IMC-002 (anti-CD47 antibody)

Samsung Biologics (207940.KS) and ImmuneOncia Therapeutics Inc. announced the successful FDA IND approval of IMC-002 under a development and...

Apr 22, 2020, 07:00 ET Samsung Biologics Earnings to Beat Consensus Again, Continues to Sign New Projects with Enhanced Virtual Support

Samsung Biologics (KRX: 207940.KS) announced Q1 earnings results on Monday, April 20th. The company posted consolidated sales of 207.2 billion Korean ...

Apr 08, 2020, 08:00 ET Samsung Biologics named Champion in 2020 CMO Leadership Awards

Samsung Biologics (207940.KS) announced that it has been awarded the 2020 CMO Leadership Awards for its excellence in the Capabilities,...

Apr 05, 2020, 20:00 ET Samsung Biologics enters into a development and manufacturing partnership with PharmAbcine for oncology and neovascular treatment

Samsung Biologics (207940.KS) entered into a strategic partnership with PharmAbcine for the development and manufacturing of PMC-402 pipeline, a next ...

Mar 30, 2020, 09:00 ET Samsung Biologics expands leadership for CDO business

Samsung Biologics (207940.KS) has appointed Eun Young Yang as vice president of business development for the company's expanded CDO (contract...

Mar 20, 2020, 08:00 ET Samsung Biologics Adds Greater Expertise and Diversity to Its Board

Samsung Biologics (207940.KS) announced the appointment and expansion of its board of directors at its 9th annual general meeting of shareholders...

Mar 16, 2020, 20:04 ET Samsung Biologics expands presence in Greater China Region with CDO partnership for Alzheimer's candidate

Samsung Biologics (207940.KS) entered into a contract development and manufacturing agreement with APRINOIA Therapeutics to develop an anti-tau...

Mar 02, 2020, 14:00 ET Samsung Biologics and STCube Enter into Development and Manufacturing Agreement for Novel Target Anticancer Drug

Samsung Biologics (207940.KS) and STCube announced a strategic development and manufacturing service agreement for STT-003 antibody, an anti-cancer...

Feb 24, 2020, 08:00 ET Samsung Biologics Confirms 'No Impact' of COVID-19 with Business Continuity Plan in Effect

Samsung Biologics has been monitoring the COVID-19 situation closely since the initial outbreak in late January and taking proactive measures...

Feb 04, 2020, 00:50 ET Samsung Biologics Reports 64% Jump in FY19 Earnings, Sees Global Expansion in 2020

Samsung Biologics, a pharmaceutical Contract Manufacturing Organization (CMO), recorded high for the fiscal year 2019, reporting 30.9% growth in...

Nov 14, 2019, 07:00 ET Samsung Biologics Enhances Its Trusted Service as the First and Only ISO27001 Certified CDMO

Samsung Biologics announced that it has obtained ISO 27001 certification, the most prestigious international standard on information security...

Nov 04, 2019, 19:22 ET Samsung Biologics and Ichnos Sciences Announce Agreement for Manufacture of ISB 830

Samsung Biologics announced the signing of a long-term agreement with Ichnos Sciences for manufacturing drug substance for ISB 830, an anti-OX40...

Aug 12, 2019, 07:00 ET Samsung BioLogics Implements Large Scale N-1 Perfusion for Commercial Application

Samsung BioLogics (SBL) has successfully performed N-1 (3,000L) perfusion with Alternating Tangential Flow (ATF) device to supply the 15,000L...

Jul 31, 2019, 07:00 ET Samsung BioLogics and UCB Sign Third Drug Manufacturing Deal

Samsung BioLogics (SBL) and UCB have agreed to an additional drug substance manufacturing deal under which SBL will also produce UCB's anti-tau...

Jun 04, 2019, 23:00 ET Samsung BioLogics Enters New Era with "First-of-its-kind" Client-Centric CMO Deal

Samsung BioLogics (SBL) recently entered a new era by signing a "first of its kind" deal with a US biopharmaceutical company valued at $7.8 million...

May 30, 2019, 07:00 ET CytoDyn and Samsung BioLogics Formalize Manufacturing Partnership

CytoDyn Inc., a late stage biotechnology company developing leronlimab (PRO 140), a CCR5 antagonist with the potential for multiple therapeutic...

May 29, 2019, 00:27 ET Samsung BioLogics to Showcase End-to-End CDMO Capabilities at BIO International 2019

For the ninth consecutive year since the company's foundation in 2011, Samsung BioLogics will be showcasing its full end-to-end CDMO capabilities at...

May 03, 2019, 02:36 ET Samsung BioLogics signs CDO(Contract Development Organization) contract with GI Innovation

Samsung BioLogics (CEO: Tae Han Kim) and GI Innovation (CEO: Soo Yeon Nam) signed a Contract Development Organization (CDO) contract for...

Mar 21, 2019, 01:42 ET Samsung BioLogics Wins 2019 CMO Leadership Awards in All Six Core Categories Three Years in a Row

Samsung BioLogics, a global leading biopharmaceutical Contract Development and Manufacturing Organization (CDMO) based in South Korea, is pleased to...

May 24, 2018, 12:05 ET Samsung BioLogics Receives an additional FDA Approval for its world largest Plant's Production

Samsung BioLogics announced today that a third monoclonal antibody Drug Substance has been licensed by the US FDA (Food and Drug Administration) for...

Apr 25, 2018, 04:09 ET Samsung BioLogics becomes the first in the South Korean pharma industry to achieve ISO 22301 Certificate

Samsung BioLogics, one of the global biologics development and manufacturing companies, announced today that it received ISO 22301 certificate, the...

Oct 11, 2017, 23:00 ET Samsung BioLogics Receives the 1st FDA Approval at the World's Largest Plant

Samsung BioLogics announced today that on October 11, 2017, it has been licensed by the US FDA (Food and Drug Administration) for the first...

Jul 04, 2017, 00:27 ET Sun Pharma & Samsung BioLogics announce strategic manufacturing tie-up for Tildrakizumab

Sun Pharma (Reuters: SUN.BO, Bloomberg: SUNP IN, NSE: SUNPHARMA, BSE: 524715, "Sun Pharmaceutical Industries Ltd" and includes its subsidiaries or...